These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 25473028)

  • 1. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting.
    Lew KY; Ng TM; Tan M; Tan SH; Lew EL; Ling LM; Ang B; Lye D; Teng CB
    J Antimicrob Chemother; 2015 Apr; 70(4):1219-25. PubMed ID: 25473028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic consumption versus the prevalence of carbapenem-resistant Gram-negative bacteria at a tertiary hospital in China from 2011 to 2017.
    Zhang D; Hu S; Sun J; Zhang L; Dong H; Feng W; Lei J; Dong Y
    J Infect Public Health; 2019; 12(2):195-199. PubMed ID: 30385238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy.
    Crusio R; Rao S; Changawala N; Paul V; Tiu C; van Ginkel J; Chapnick E; Kupfer Y
    Scand J Infect Dis; 2014 Jan; 46(1):1-8. PubMed ID: 24206450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a Carbapenem Antimicrobial Stewardship Program on Patient Outcomes.
    Seah VXF; Ong RYL; Lim ASY; Chong CY; Tan NWH; Thoon KC
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28717037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of carbapenem de-escalation regardless of microbiological results: A propensity score analysis.
    Sadyrbaeva-Dolgova S; Aznarte-Padial P; Pasquau-Liaño J; Expósito-Ruiz M; Calleja Hernández MÁ; Hidalgo-Tenorio C
    Int J Infect Dis; 2019 Aug; 85():80-87. PubMed ID: 31075508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of antimicrobial stewardship program on antimicrobial usage and detection rate of multidrug-resistant gram-negative bacteria].
    Xu YL; Hu LM; Xie ZZ; Dong YW; Dong L
    Zhonghua Er Ke Za Zhi; 2019 Jul; 57(7):553-558. PubMed ID: 31269557
    [No Abstract]   [Full Text] [Related]  

  • 7. A de-escalation protocol for febrile neutropenia cases and its impact on carbapenem resistance: A retrospective, quasi-experimental single-center study.
    Alshukairi A; Alserehi H; El-Saed A; Kelta M; Rehman JU; Khan FA; Alsalmi H; Alattas M; Aslam M
    J Infect Public Health; 2016; 9(4):443-51. PubMed ID: 26688375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
    Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
    J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptance and outcome of interventions in a meropenem de-escalation antimicrobial stewardship program in pediatrics.
    Rungsitsathian K; Wacharachaisurapol N; Nakaranurack C; Usayaporn S; Sakares W; Kawichai S; Jantarabenjakul W; Puthanakit T; Anugulruengkitt S
    Pediatr Int; 2021 Dec; 63(12):1458-1465. PubMed ID: 33740838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
    Rattanaumpawan P; Werarak P; Jitmuang A; Kiratisin P; Thamlikitkul V
    BMC Infect Dis; 2017 Mar; 17(1):183. PubMed ID: 28249572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization and risk factors for carbapenem-resistant Gram-negative bacilli colonization in children: emergence of NDM-producing Acinetobacter baumannii in a newborn intensive care unit in Turkey.
    Karaaslan A; Soysal A; Altinkanat Gelmez G; Kepenekli Kadayifci E; Söyletir G; Bakir M
    J Hosp Infect; 2016 Jan; 92(1):67-72. PubMed ID: 26601601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the potential impact of a carbapenem de-escalation program in an academic healthcare system.
    Ahmad F; Pogue JM; Marchaim D; Chopra T; Bheemreddy S; Lee J; Mudegowdra NS; Chaudhry A; Kaye KS
    J Infect Public Health; 2014 Feb; 7(1):50-3. PubMed ID: 24210246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of various antimicrobial stewardship programs on antimicrobial usage and resistance among common gram-negative bacilli causing health care-associated infections: A multicenter comparison.
    Lai CC; Shi ZY; Chen YH; Wang FD
    J Microbiol Immunol Infect; 2016 Feb; 49(1):74-82. PubMed ID: 26586483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of improving carbapenem use via prospective review and feedback in a multidisciplinary antimicrobial stewardship programme.
    Teng CB; Ng TM; Tan MW; Tan SH; Tay M; Lim SF; Ling LM; Ang BS; Lye DC
    Ann Acad Med Singap; 2015 Jan; 44(1):19-25. PubMed ID: 25703493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbapenem-resistant organisms (CRO): Information for healthcare workers.
    J Hosp Infect; 2016 Jan; 92(1):99-101. PubMed ID: 27158708
    [No Abstract]   [Full Text] [Related]  

  • 16. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.
    Nørgaard SM; Jensen CS; Aalestrup J; Vandenbroucke-Grauls CMJE; de Boer MGJ; Pedersen AB
    Antimicrob Resist Infect Control; 2019; 8():170. PubMed ID: 31709047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
    Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
    Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacist recommendations for carbapenem de-escalation in urinary tract infection within an antimicrobial stewardship program.
    Sadyrbaeva-Dolgova S; Aznarte-Padial P; Jimenez-Morales A; Expósito-Ruiz M; Calleja-Hernández MÁ; Hidalgo-Tenorio C
    J Infect Public Health; 2020 Apr; 13(4):558-563. PubMed ID: 31685404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
    Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
    Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of an antimicrobial stewardship bundle for patients with Clostridium difficile infection.
    Brumley PE; Malani AN; Kabara JJ; Pisani J; Collins CD
    J Antimicrob Chemother; 2016 Mar; 71(3):836-40. PubMed ID: 26661392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.